Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 232,122,118 papers from all fields of science
Search
Sign In
Create Free Account
ICRF 154
Known as:
ICRF-154
National Institutes of Health
Create Alert
Alert
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
A Three-Dimensional Quantitative Structure-Activity Analysis of a New Class of Bisphenol Topoisomerase IIα Inhibitors
Hong Liang
,
Xing Wu
,
J. Yalowich
,
B. Hasinoff
Molecular Pharmacology
2008
Corpus ID: 32101889
After the identification of a new lead bisphenol compound that had good topoisomerase IIα (EC 5.99.1.3) inhibitory activity, a…
Expand
2008
2008
Antitumor activity of MST-16, a novel derivative of bis(2,6-dioxopiperazine), in murine tumor models
T. Narita
,
S. Yaguchi
,
+4 authors
S. Tsukagoshi
Cancer Chemotherapy and Pharmacology
2008
Corpus ID: 9833883
SummaryWe studied the antitumor activity of newly synthesized bis(1-acyloxymethyl) derivatives of 4,4′-(1,2-ethanediyl)bis(2,6…
Expand
2006
2006
A Three-Dimensional Quantitative Structure-Activity Relationship Study of the Inhibition of the ATPase Activity and the Strand Passing Catalytic Activity of Topoisomerase IIα by Substituted Purine…
L. Jensen
,
Hong Liang
,
R. Shoemaker
,
M. Grauslund
,
M. Sehested
,
B. Hasinoff
Molecular Pharmacology
2006
Corpus ID: 13699683
Based on the topoisomerase IIα catalytic inhibitory activity of a previous hit compound, NSC35866, we screened 40 substituted…
Expand
2003
2003
Evidence from Studies with Intact Mammalian Cells That Merbarone and bis(Dioxopiperazine)s Are Topoisomerase II Poisons
R. Snyder
Drug and chemical toxicology (New York, N.Y. )
2003
Corpus ID: 21771389
Abstract A Chinese hamster V79 cell-based assay for detection of topoisomerase II (topo II) poisons and catalytic inhibitors has…
Expand
1999
1999
MST-16, a novel bis-dioxopiperazine anticancer agent, ameliorates doxorubicin-induced acute toxicity while maintaining antitumor efficacy.
M. Yoshida
,
Yoshihiko Maehara
,
K. Sugimachi
Clinical Cancer Research
1999
Corpus ID: 11510042
MST-16 [4,4-1,2-(ethanediyl)bis(1-isobutoxycarbonyl-oxy-methyl-2,6-pipera zinedione)], recently approved as an oral anticancer…
Expand
1998
1998
MST-16, a novel derivative of bis(2,6-dioxopiperazine), synergistically enhances the antitumor effects of anthracyclines
S. Inutsuka
,
H. Baba
,
Y. Maehara
,
K. Sugimachi
Cancer Chemotherapy and Pharmacology
1998
Corpus ID: 10746917
MST-16, a derivative of bis(2,6-dioxopiperazine), is a newly developed anticancer agent that is potentially effective in…
Expand
1997
1997
Translocation t(7;11)(P15;P15) in a patient with therapy-related acute myeloid leukemia following bimolane and ICRF-154 treatment for psoriasis.
Y. Xue
,
Y. Guo
,
X. Xie
Leukemia research : a Forum for Studies on…
1997
Corpus ID: 24527172
1994
1994
bis(2,6-dioxopiperaxine) derivatives, topoisomerase II inhibitors which do not form a DNA cleavable complex, induce thymocyte apoptosis.
Y. Onishi
,
Y. Azuma
,
H. Kizaki
Biochemistry and molecular biology international
1994
Corpus ID: 39823816
Internucleosomal DNA fragmentation and cell death were induced dose- and time-dependently by incubation of mouse thymocytes with…
Expand
1989
1989
Synthesis and antitumor properties of N1-acyloxymethyl derivatives of bis(2,6-dioxopiperazines).
J. Cai
,
H. Shu
,
+6 authors
M. Takase
Chemical and pharmaceutical bulletin
1989
Corpus ID: 24832619
Many N1-acyloxymethyl derivatives VI of bis(2,6-dioxopiperazine) I, ICRF-154, were prepared and tested for antitumor activity…
Expand
1984
1984
Bimolane: structure determination indicates anticancer activity is attributable to ICRF-154.
N. Camerman
,
A. Hempel
,
A. Camerman
Science
1984
Corpus ID: 30297594
X-ray diffraction studies of crystals from samples of bimolane synthesized in China and in the United States showed that the…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE